2HA Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Spero Therapeutics Inc

Watchlist Manager

Watchlist

Price: 1.811 EUR -3.05% Market Closed

Market Cap: €3m

S	Spero Therapeutics Inc F:2HA	US
T	Tegna Inc F:GTT	US
F	First Majestic Silver Corp XMUN:FMV	CA

Profitability Summary

Spero Therapeutics Inc's profitability score is 32/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Healthy Operating Margin

11%

Negative 3Y Average Operating Margin

-45%

Operating Margin is Increasing

-56% > 11%

Healthy Net Margin

13%

Negative 3Y Average Net Margin

-42%

Net Margin is Increasing

-50% > 13%

Negative Free Cash Flow Margin

-19%

Negative 3Y Average Free Cash Flow Margin

-26%

Declining Free Cash Flow Margin

14% > -19%

Positive ROE

16%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-43%

ROIC is Increasing

-172% > 18%

View All

Hide

Collapse

32 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.